Influence of synthesis conditions on the optical properties of Naregeo<sub>4</sub> phosphors with olivine structure
Журнал неорганической химии / Russian Journal of Inorganic Chemistry · 2025
DOI: 10.7868/s3034560x25010014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Журнал неорганической химии / Russian Journal of Inorganic Chemistry, 2025. Verfasst von A. A. Melentsova.
Abstract (Originalsprache)
The NaGdGeO4, NaY0.975Tm0.025GeO4, NaY0.975Bi0.025GeO4, NaY0.875Bi0.025Eu0.1GeO4 samples were synthesized by different methods. According to powder X-ray diffraction data, the germanates crystallize in orthorhombic system pr.gr. Pnma, Z = 4. The influence of synthesis conditions, particularly different annealing modes, on morphological and optical properties of the samples were evaluated. The luminescence properties of NaY0.975Tm0.025GeO4, NaGdGeO4 and NaY0.975Bi0.025GeO4, NaY0.875Bi0.025Eu0.1GeO4 compounds were studied in the near infrared range (1100 – 2100 nm, λex = 808 nm), in the UV region (300–320 nm, λex = 257 nm) and in the UV and visible wavelength range (300 – 700 nm, λex = 298 nm), respectively. The influence of annealing parameters on the persistent luminescence duration of the last compositions was investigated additionally.
Zitieren
APA
Melentsova, A. A. (2025). Influence of synthesis conditions on the optical properties of Naregeo4 phosphors with olivine structure. Журнал неорганической химии / Russian Journal of Inorganic Chemistry. https://doi.org/10.7868/s3034560x25010014
Vancouver
Melentsova AA. Influence of synthesis conditions on the optical properties of Naregeo4 phosphors with olivine structure. Журнал неорганической химии / Russian Journal of Inorganic Chemistry. 2025. doi:10.7868/s3034560x25010014
BibTeX
@article{Melentsova2025,
author = {Melentsova, A. A.},
title = {Influence of synthesis conditions on the optical properties of Naregeo4 phosphors with olivine structure},
journal = {Журнал неорганической химии / Russian Journal of Inorganic Chemistry},
year = {2025},
doi = {10.7868/s3034560x25010014}
}
EUVIMED